002923.SHE Zhuhai Rundu Pharmaceutical Co Ltd Class A
- Market cap
- CNY 3.03B
- P/E
- 53.3x
- P/B
- 2.67x
- ROE
- 7.9%
- Dividend yield
- 2.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002923.SHE undervalued?
Graham number002923.SHE trades 151.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhuhai Rundu Pharmaceutical Co Ltd Class A fundamental analysis
No fundamental analysis for Zhuhai Rundu Pharmaceutical Co Ltd Class A yet.
Zhuhai Rundu Pharmaceutical Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the …
Full company profileZhuhai Rundu Pharmaceutical Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhuhai Rundu Pharmaceutical Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 652M | 779M | 1.04B | 1.36B | 1.25B | 1.19B | 1.37B | 1.29B | 1.18B | 1.18B | 1.43B |
| Gross Profit | 417M | 504M | 782M | 970M | 761M | 711M | 736M | 607M | 490M | 454M | 614M |
| Operating Income | 85.7M | 104M | 120M | 134M | 154M | 154M | 181M | 86.3M | 44.1M | 22.0M | 141M |
| EBITDA | 126M | 138M | 154M | 174M | 202M | 214M | 258M | 214M | 194M | 96.7M | 110M |
| Net Income | 87.5M | 90.7M | 107M | 119M | 136M | 140M | 155M | 66.9M | 39.9M | -63.5M | 87.5M |
| EPS | 0.36 | 0.37 | 0.32 | 0.35 | 0.41 | 0.41 | 0.46 | 0.20 | 0.12 | -0.19 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 617M | 706M | 1.14B | 1.33B | 1.51B | 1.91B | 2.29B | 2.23B | 2.19B | 2.03B | 2.08B |
| Total Liabilities | 218M | 217M | 267M | 386M | 476M | 797M | 1.09B | 1.05B | 1.04B | 990M | 978M |
| Shareholders' Equity | 398M | 489M | 871M | 940M | 1.04B | 1.11B | 1.20B | 1.18B | 1.15B | 1.04B | 1.10B |
| Cash & Short-term Investments | 150M | 168M | 183M | 198M | 296M | 250M | 221M | 214M | 207M | 256M | 319M |
| Total Debt | 113M | 85.2M | 47.3M | 29.5M | 69.4M | 287M | 468M | 502M | 392M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 94.1M | 58.0M | 159M | 151M | 250M | 206M | 135M | 173M | 211M | 104M | - |
| Capital Expenditure | 63.9M | 36.4M | 115M | 240M | 257M | 376M | 252M | 175M | 81.3M | 18.0M | 16.2M |
| Free Cash Flow | 30.2M | 21.6M | 43.7M | -88.7M | -6.40M | -171M | -117M | -1.85M | 130M | 86.4M | 157M |
| Ratios | |||||||||||
| ROE | 22.0% | 18.5% | 12.3% | 12.6% | 13.1% | 12.6% | 13.0% | 5.7% | 3.5% | -6.1% | 7.9% |
| ROA | 14.2% | 12.8% | 9.4% | 9.0% | 9.0% | 7.3% | 6.8% | 3.0% | 1.8% | -3.1% | 4.2% |
| Net Profit Margin | 13.4% | 11.6% | 10.2% | 8.7% | 10.8% | 11.7% | 11.3% | 5.2% | 3.4% | -5.4% | 6.1% |
| Debt to Equity | 0.28x | 0.17x | 0.05x | 0.03x | 0.07x | 0.26x | 0.39x | 0.43x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhuhai Rundu Pharmaceutical Co Ltd Class A dividends
- Dividend yield
- 2.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 30, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 64.1M | 0.19 | - |
| 2024 | CNY 84.7M | 0.25 | 212.4% |
| 2023 | CNY 102M | 0.31 | 153.0% |
| 2022 | CNY 74.3M | 0.22 | 47.8% |
| 2021 | CNY 74.3M | 0.22 | 53.2% |
| 2020 | CNY 74.4M | 0.22 | 54.7% |
| 2019 | CNY 74.2M | 0.22 | 62.4% |
| 2018 | CNY 70.0M | 0.21 | 65.5% |
| 2017 | CNY 5.11M | 0.02 | 5.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 31, 2023.
Who owns Zhuhai Rundu Pharmaceutical Co Ltd Class A
- Insiders 57.02%
- Institutions 1.37%
- Public & others 41.61%
- Shares outstanding 335M
- Free float 129M
Zhuhai Rundu Pharmaceutical Co Ltd Class A company profile
- Company name
- Zhuhai Rundu Pharmaceutical Co Ltd Class A
- Ticker
- 002923.SHE
- ISIN
- CNE1000033G8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,655
- Fiscal year end
- December
- Address
- No. 6, North Airport Road, Zhuhai, China, 519041
- Phone
- 86 75 6763 0088
- Website
- rdpharma.cn
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, quality research, and registration of chemical drugs. In addition, it provides branding services of drug products, as well as academic services. The company was founded in 1999 and is headquartered in Zhuhai, China.
Zhuhai Rundu Pharmaceutical Co Ltd Class A management
6- Mr. Jie LiuGM & Director · born 1976
- Mr. Shenhua ShiDeputy GM, CFO & Accounting Supervisor · born 1963
- Mr. Jun SuDeputy GM & Board Secretary · born 1981
- Mr. Qiang CaiDeputy General Manager · born 1978
- Mr. Wei ChenDeputy General Manager · born 1981
- Mr. Jun LiuDeputy General Manager · born 1968